Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 166 participants.
Also called NCT04029480
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 166 participants
- Sponsor
- Registry
-
NCT04029480 -
2022-501085-21-00 -
U1111-1279-3984 -
2017-003455-35
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Belgium, Canada, Colombia, Costa Rica, Dominican Republic, France, Guatemala, Hungary, Israel, Italy, Malaysia, Mauritius, Mexico, Philippines, Poland, Russia, Saudi Arabia, Türkiye, Ukraine, United Arab Emirates, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT04029480. Randomized; double masking; primary purpose treatment. Start 2019-10-08 (actual); primary completion 2025-04-11 (actual). Results posted on 2025-10-31.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059)
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Ertugliflozin 5 mg
- Intervention (Drug)
- Ertugliflozin 15 mg
- Intervention (Drug)
- Placebo to ertugliflozin 15 mg
- Intervention (Drug)
- Placebo to ertugliflozin 5 mg
- Intervention (Biological)
- Insulin
- Intervention (Drug)
- Metformin
- Lead sponsor
- Merck Sharp & Dohme LLC
- Collaborator
- Pfizer
Record details
- Record id
cardio:ct-nct04029480- Content hash
7128cdcc4f2930d0ee2b086957162ec4abff3b3decd109a5f5b997132af6748d